Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Gross Margin
Operating Margin
EBITDA Margin
Net Margin
Current Ratio0.050.1518.6912.5113.056.183.016.754.748.697.200.43
Quick Ratio0.050.1518.6912.5113.056.183.016.754.748.697.200.43
Debt / Equity
ROE120.45%1734.41%-74.17%-46.25%-33.94%-84.54%-221.94%-81.27%-165.47%-84.81%-97.17%73.85%
ROA55.30%-6670.82%-70.22%-42.05%-30.91%-70.51%-146.74%-68.60%-123.59%-71.79%-80.34%-20.44%
Asset Turnover
Book Value / Share0.55-0.254.057.2812.1910.66

Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Israel, specializing in the development of innovative capsule-based screening technology for colorectal cancer detection. Founded in 2004, the company focuses on its proprietary C-Scan system, which includes an ingestible capsule that uses ultra-low-dose X-rays to non-invasively scan the inner lining of the colon for precancerous polyps and structural abnormalities. This capsule-based approach aims to provide patient-friendly, preparation-free colorectal screening to increase adherence and enable early intervention. The system comprises the C-Scan capsule, a disposable tracking device attached externally to the patient, and analytic software for data processing and report generation. Check-Cap's technology represents a significant advancement in non-invasive cancer diagnostics, aligning with the broader healthcare sector's focus on early detection and preventive medicine.